# EDGAR Filing Document

**Accession Number:** 0001829635
**File Stem:** 0001104659-25-122526
**Filing Date:** 2025-12
**Character Count:** 2403
**Document Hash:** f8600a71c646c61c5ec459bbf71c2821
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-122526.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001104659-25-122526

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251218

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Transcode Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001829635
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811065054
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 6 LIBERTY SQUARE
- **STREET 2:** #2382
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 857-301-6857

**MAIL ADDRESS:**
- **STREET 1:** 6 LIBERTY SQUARE
- **STREET 2:** #2382
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

December 18, 2025

**VIA EDGAR**

U.S. Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549-3233

Attention: Mr. Alan Campbell

**Re: TransCode Therapeutics, Inc.**

**Acceleration Request for Registration Statement on Form S-3**

**File No. 333-292112**

Dear Mr. Campbell:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), TransCode Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to December 22, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072.

Please contact Adam V. Johnson of Goodwin Procter LLP via telephone at (212) 459-7072 or via e-mail (AdamJohnson@goodwinlaw.com) with any questions.

---

| |
|:---|
| Sincerely, |
| TRANSCODE THERAPEUTICS, INC. |
| /s/ Philippe P. Calais |
| Philippe P. Calais<br> Chief Executive Officer |

---

cc: Thomas Fitzgerald, *TransCode Therapeutics, Inc.* <br> Michael Bison, *Goodwin Procter LLP* <br> Adam V. Johnson, *Goodwin Procter LLP*